Variable | Below median GLS | Above median GLS | p-value |
---|---|---|---|
(n = 65) | (n = 52) | ||
Age, years | 69 (63–76) | 71 (67–76) | 0.761 |
Female gender, % | 33.8 | 21.2 | 0.130 |
BMIa, kg/m2 | 26.0 (22.6-30.2) | 26.3 (24.5-30.3) | 0.214 |
NYHAb class III-IV, % | 23.1 | 30.8 | 0.349 |
Systolic BPc, mmHg | 132 (120–147) | 120 (110–140) | 0.178 |
Diastolic BPc, mmHg | 77 (70–82) | 77 (69–84) | 0.889 |
Heart rate, beats/min | 64 (56–76) | 70 (62–78) | 0.188 |
HFd duration, months | 9 (6–12) | 12 (6–24) | 0.216 |
Pervious MIe, % | 33.8 | 44.2 | 0.251 |
Hypertension, % | 67.7 | 59.6 | 0.395 |
Atrial fibrillation, % | 24.6 | 40.4 | 0.068 |
ICDf, % | 9.5 | 13.5 | 0.507 |
Diabetes, % | 20 | 25 | 0.518 |
ApoplexiaCerebri/TCIg, % | 12.3 | 23.1 | 0.124 |
ACE-Ih, % | 73.8 | 59.6 | 0.140 |
ARBi, % | 21.5 | 32.7 | 0.174 |
Beta-blocker, % | 87.7 | 86.5 | 0.853 |
MRAj, % | 14.1 | 28.8 | 0.051 |
Diuretics, % | 69.2 | 76.9 | 0.354 |
Hemoglobine, mmol/l | 8.5 (7.0-9.0) | 8.8 (8.0-9.3) | 0.215 |
Creatinine, umol/l | 80 (68–97) | 95 (73–119) | 0.254 |
eGFRk, ml/min/1,73 m2 | 82 (66–98) | 70 (51–95) | 0.244 |